Investigational Drug Ralinepag Shows Significant Improvement in Pulmonary Arterial Hypertension Outcomes

New data from the ADVANCE Outcomes trial indicates that investigational drug ralinepag significantly reduced clinical worsening events by 55% in pulmonary arterial hypertension (PAH) patients compared to placebo. The oral prostacyclin receptor agonist also improved a composite clinical outcome by 47% and enhanced other key markers, suggesting a notable therapeutic benefit for this serious condition.